Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2025 16:30 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to...